{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3"},{"groupId":"OG001","value":"5.3"},{"groupId":"OG002","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"description":"Bridge to Stem Cell Transplant (SCT) defined as the percentage of patients who received SCT subsequent to achieving an Investigator-determined outcome from Tagraxofusp that was deemed by the Investigator to enable an SCT","groups":[{"description":"First-line BPDCN patients enrolled across stages","id":"OG000","title":"First-line BPDCN"},{"description":"R/R BPDCN patients enrolled across stages","id":"OG001","title":"R/R BPDCN"},{"description":"AML patients enrolled in stages 1 and 2","id":"OG002","title":"Acute Myeloid Leukemia"}],"paramType":"NUMBER","populationDescription":"Efficacy population including evaluable patients treated at 12 μg/kg/day in the first-line BPDCN, R/R BPDCN and AML","reportingStatus":"POSTED","timeFrame":"at pre-defined intervals up to achievement of outcome enabling an SCT for a period, up to 5 years","title":"Bridge to SCT in First-line BPDCN, R/R BPDCN and AML","type":"SECONDARY","unitOfMeasure":"percentage of evaluable patients"}